Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

In vivo macrophage engineering for renal cancer therapy

Nature Cancer volume 6, pages 743–745 (2025)Cite this article

Subjects

Chimeric antigen receptor (CAR) macrophage therapy has shown promising activity in preclinical models of solid tumors. A platform that combines CAR technology with lipid nanoparticles for in vivo macrophage engineering is now shown to generate pro-inflammatory CAR macrophages with sustained tumoricidal activity as effective therapy against renal cell carcinoma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic of hydrogel particles containing CAR-mLNPs that target macrophages for enhanced recognition of RCC cells.

References

  1. Jing, W. et al. Nat. Cancer https://doi.org/10.1038/s43018-025-00950-1 (2025).

    Article  PubMed  Google Scholar 

  2. Klichinsky, M. et al. Nat. Biotechnol. 38, 947–953 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Shah, Z. et al. Cell Stem Cell 31, 803–817.e6 (2024).

    Article  CAS  PubMed  Google Scholar 

  4. Noy, R. & Pollard, J. W. Immunity 41, 49 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lei, A. et al. Nat. Immunol. 25, 102–116 (2023).

    Article  PubMed  Google Scholar 

  6. Morrissey, M. A. et al. eLife 7, e36688 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhang, L. et al. J. Hematol. Oncol. 13, 153 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ackermann, M. et al. Nat. Protoc. 17, 513–539 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Abdin, S. M. et al. J. Immunother. Cancer 11, e007705 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chen, C. et al. Sci. Transl. Med 14, 1128 (2022).

    Article  Google Scholar 

  11. Hou, X., Zaks, T., Langer, R. & Dong, Y. Nat. Rev. Materials 6, 1078–1094 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany

    Débora Basílio-Queirós & Nico Lachmann

  2. Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover Medical School, Hannover, Germany

    Nico Lachmann

  3. REBIRTH, Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany

    Nico Lachmann

  4. Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany

    Nico Lachmann

  5. Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Hannover, Germany

    Nico Lachmann

Authors
  1. Débora Basílio-Queirós
    View author publications

    Search author on:PubMed Google Scholar

  2. Nico Lachmann
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Nico Lachmann.

Ethics declarations

Competing interests

N.L. is author of a patent application PCT/EP2018/061574 in the scope of macrophage manufacturing. D.B.-Q. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Basílio-Queirós, D., Lachmann, N. In vivo macrophage engineering for renal cancer therapy. Nat Cancer 6, 743–745 (2025). https://doi.org/10.1038/s43018-025-00912-7

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-025-00912-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing